Replies to post #16597 on The Rising Influence of Rising Affluence

[biotech_researcher]

"PFE lost a lot of revenue (compared to 1Q17) to patent expirations, e.g. Lyrica. This was known beforehand, so it shouldn't be a "show stopper" for anybody."

Well, the analyst did point out that PFE did miss their sales target....